MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Silicon Valley Tech Veteran and Former Illumina CEO Francis deSouza Joins 4baseCare’s Advisory Board

NextEdge Admin

31 Jul 2024

1 min 33 sec

4baseCare, an Illumina Accelerator Company offering cutting-edge precision oncology solutions using advanced genomics and digital health technology, has appointed Francis deSouza to its advisory board. DeSouza, renowned for his leadership as the CEO of Illumina, played a crucial role in making genomics more accessible worldwide by significantly reducing sequencing costs and introducing innovative clinical solutions. During his tenure from 2016 to 2023, Illumina expanded its operations to over 150 countries. “I am excited to join 4baseCare and work with Hitesh and Kshitij. The company’s mission to make genomics accessible and affordable for under-represented populations deeply resonates with me,” deSouza stated. Hitesh Goswami, CEO and Co-Founder of 4baseCare, commented, “Francis deSouza’s extensive experience in growing Illumina aligns with our plan to expand our genomics capabilities in SE Asia and the Middle East. We look forward to working with him to achieve our vision of making genomics accessible and positively impacting millions of cancer patients in the region.”